Identification of a suitable nonhuman primate (NHP) model of COVID-19 remains
challenging. Here, we characterized severe acute respiratory syndrome coronavirus 2 …

Understanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for
effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb …

The current coronavirus disease (COVID‐19) outbreak, caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has raised the possibility of potential …

COVID-19 is the first known pandemic caused by a coronavirus, SARS-CoV-2, which is the
third virus in the family Coronaviridae to cause fatal infections in humans after SARS-CoV …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an
unprecedented global pandemic of COVID-19. Animal models are urgently needed to study …

The current COVID‐19 global pandemic, caused by severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) of probable bat origin, has highlighted the ongoing need for a …

The emerging SARS-CoV-2 variants, commonly with many mutations in S1 subunit of spike
(S) protein are weakening the efficacy of the current vaccines and antibody therapeutics …

There is an urgent need for a safe and protective vaccine to control the global spread of
SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective …

Pulmonary fibrosis is the end stage of a broad range of heterogeneous interstitial lung
diseases and more than 200 factors contribute to it. In recent years, the relationship between …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus
causing acute respiratory tract infection in humans. The virus has the characteristics of rapid …